Physician profile
Michael R Vaughn
NPI 1598889420
$6,226.77
in general payments reported to CMS, 2019-2025
24 companies · $980 in 2025
The $980 reported for 2025 was more than what 82% of Addiction Psychiatry providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $735 · 2020: $211 · 2021: $839 · 2022: $994 · 2023: $1,466 · 2024: $1,003 · 2025: $980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,347 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,347.19 |
| Education | $101.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,239.86 | 2021-2025 | Vraylar |
| Lundbeck LLC | $735.43 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $724.14 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $608.96 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $476.28 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $373.80 | 2020-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $361.34 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $334.92 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $312.89 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $229.06 | 2020-2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $170.67 | 2023-2024 | Quviviq |
| Allergan, INC. | $91.96 | 2019-2020 | |
| Axsome Therapeutics, INC. | $87.54 | 2024-2025 | Auvelity |
| Bausch Health US, LLC | $82.86 | 2021-2025 | Wellbutrin, Aplenzin |
| Eisai INC. | $73.84 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $60.14 | 2022-2025 | Qelbree |
| Shire North American Group INC | $55.69 | 2019 | |
| Orexo US, INC. | $51.31 | 2019-2024 | Zubsolv |
| Corium, LLC | $34.75 | 2022-2023 | Azstarys |
| Ironshore Pharmaceuticals INC. | $34.66 | 2019-2020 | |
| Indivior INC. | $28.49 | 2021-2022 | |
| Noven Therapeutics, LLC | $21.37 | 2023 | Secuado, Xelstrym |
| Sunovion Pharmaceuticals INC. | $19.90 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.91 | 2024 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Vaughn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.